Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00393718 on ClinicalTrials.gov · last registry update 2017-03-08

Finished November 2007, after enrolling 400 people. Primary outcome, as filed: Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 400
Started: 2006-11
Primary completion: 2007-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.